Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487964 | 0.80 | JAK2 (0.40) | JAK2TYK2ACLYMAT2APDE4B | |
| SCHEMBL4882519 | 0.78 | MAT2A (0.45) | JAK2TYK2ACLYMAT2AADORA2A | |
| SCHEMBL3986451 | 0.77 | JAK2 (0.36) | JAK2TYK2ACLYMAT2AADORA2A | |
| SCHEMBL3989442 | 0.73 | NPBWR1 (0.41) | JAK2TYK2MAPK1 | |
| SCHEMBL4882430 | 0.70 | MAT2A (0.46) | JAK2TYK2MAT2AADORA2ANPC1 | |
| SCHEMBL4877684 | 0.69 | MAT2A (0.39) | JAK2TYK2MAT2AMAPK1KAT6A | |
| SCHEMBL4501812 | 0.69 | TYK2 (0.43) | JAK2TYK2ACLYFGFR1MAT2A | |
| SCHEMBL4745803 | 0.67 | KCNH2 (0.35) | MAT2AADORA2AADORA2BADORA1MAPK1 | |
| SCHEMBL4501834 | 0.67 | ALDH1A1 (0.38) | JAK2TYK2ADORA2AADORA2BADORA1 | |
| SCHEMBL4492304 | 0.66 | ACLY (0.31) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2009-07-23 | — | — | US | disclosed |
| EP-2034993-A2 | PYRAZINONES AS CELLULAR PROLIFERATION INHIBITORS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080194585-A1 | Fungicidal Pyrazine Derivatives | SHARPE PAULA LOUISE | 2008-08-14 | — | — | US | disclosed |
| WO-2007149448-A2 | PYRAZINONES AS CELLULAR PROLIFERATION INHIBITORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194585-A1 | Fungicidal Pyrazine Derivatives | CBR3, CBR1, NR0B1 | JAK2 3907/4885TYK2 2617/4885ACLY 2239/4885 |
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | MKI67, NR0B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | JAK2 2128/4885TYK2 3405/4885ACLY 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.